Sodium chromate Cr-51 API Manufacturers

compare suppliers & get competitive offers

teaser-1024x654-1
No suppliers found
Sorry, there are currently no suppliers listed for this ingredient. Hopefully we can help you with other ingredients.
Notify me!
Want to be the first to find out when a supplier for Sodium chromate Cr-51 is listed?

Join our notification list by following this page.

List your company
Are you a supplier of Sodium chromate Cr-51 or other APIs and are you looking to list your company on Pharmaoffer?

Click the button below to find out more

Find CDMO
Looking for a CDMO/CMO that can help you with your pharmaceutical needs?

Click the button below to switch over to the contract services area of Pharmaoffer.

Looking for Sodium chromate Cr-51 API 10039-53-9?

Description:
Here you will find a list of producers, manufacturers and distributors of Sodium chromate Cr-51. You can filter on certificates such as GMP, FDA, CEP, Written Confirmation and more. Send inquiries for free and get in direct contact with the supplier of your choice.
API | Excipient name:
Sodium chromate Cr-51 
Synonyms:
Chromate (51 Cr) de sodium , Cromato sodico (51 Cr) , Natrii chromas (51 Cr) , Sodium chromate (51 Cr) , Sodium chromate (51Cr) , Sodium chromate Cr 51  
Cas Number:
10039-53-9 
DrugBank number:
DB09380 
Unique Ingredient Identifier:
XI776WYU0N

General Description:

Sodium chromate Cr-51 is a chemical compound identified by the CAS number 10039-53-9. It is known for its distinct pharmacological properties and applications.

Classification:

Sodium chromate Cr-51 belongs to the class of inorganic compounds known as miscellaneous chromates. These are inorganic compounds in which the largest metallic oxoanion is chromate, to which either no atom or a non metal atom is bonded, classified under the direct parent group Miscellaneous chromates. This compound is a part of the Inorganic compounds, falling under the Mixed metal/non-metal compounds superclass, and categorized within the Miscellaneous mixed metal/non-metals class, specifically within the Miscellaneous metallic oxoanionic compounds subclass.

Categories:

Sodium chromate Cr-51 is categorized under the following therapeutic classes: Radioactive Diagnostic Agent. These classifications highlight the drug's diverse therapeutic applications and its importance in treating various conditions.

Sodium chromate Cr-51 is a type of Diagnostic agents


Diagnostic agents are a crucial category of pharmaceutical active pharmaceutical ingredients (APIs) used in the field of medical diagnostics. These agents play a vital role in diagnosing various diseases and conditions by aiding in the visualization and identification of specific biomarkers or structures within the body.

Diagnostic agents encompass a wide range of substances, including contrast agents, radiopharmaceuticals, and imaging agents. Contrast agents are commonly used in medical imaging techniques such as X-rays, magnetic resonance imaging (MRI), and computed tomography (CT) scans. They enhance the visibility of certain tissues or organs, allowing healthcare professionals to detect abnormalities more accurately.

Radiopharmaceuticals are another type of diagnostic agent that combines a radioactive component with a pharmaceutical compound. These agents emit radiation that can be detected by specialized imaging equipment, enabling the visualization of metabolic processes and the identification of abnormal cellular activity.

Imaging agents are designed to target specific molecular structures or biomarkers within the body. They can be used to detect and visualize specific proteins, enzymes, or receptors associated with certain diseases or conditions. By targeting these specific biomarkers, imaging agents provide valuable information about the presence, location, and extent of a disease, aiding in diagnosis and treatment planning.

Overall, diagnostic agents are essential tools in modern medicine, facilitating accurate and timely diagnoses. These pharmaceutical APIs enable healthcare professionals to identify and monitor diseases at an early stage, leading to better patient outcomes and improved treatment strategies.